[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stent-implantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stent-implantation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,76,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632255","ffr-guided-revascularization-in-atherosclerotic-renal-artery-stenosis-100632255",false,"NCT07511309","FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis","Fractional Flow Reserve-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial","FARS","Inclusion Criteria:\n\n1. Renal artery diameter stenosis ≥60%;\n2. Office systolic blood pressure ≥ 160 mmHg and\u002For office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and\u002For office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses;\n3. Serum creatinine \\\u003C 264 μmol\u002FL (3.0 mg\u002FdL);\n4. Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL\u002Fmin;\n\nExclusion Criteria:\n\n1. Unstable clinical condition rendering the patient intolerant to revascularisation therapy;\n2. Urinary protein ≥2+;\n3. Contrast medium allergy;\n4. Renal artery anatomy unsuitable for revascularisation therapy;\n5. Reference vessel diameter \\\u003C3.5mm or \\>8mm.\n6. Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis);\n7. Reference vessel diameter \\\u003C 3.5 mm or \\> 8 mm.","ALL","40 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"NA","For patients with atherosclerotic renal artery stenosis, the results of randomized controlled trials published in recent years have failed to demonstrate that renal artery stenting is superior to optimal medical therapy. However, these studies still have limitations.\n\nFractional flow reserve (FFR) has been extensively studied in coronary artery disease, and it has been established that FFR-guided revascularization is superior to both angiography-guided percutaneous coronary intervention and medical therapy alone. Whether FFR can guide interventional treatment in patients with renal artery stenosis and hypertension is currently a hot topic in the field of renal artery stenosis research.\n\nEligible patients meeting the inclusion criteria were enrolled. Pharmacologically induced FFR values were measured as the baseline. Patients with FFR ≥ 0.8 were randomly assigned to either the medical therapy group or the stenting group, while patients with FFR \\\u003C 0.8 underwent stent implantation. Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.",[28,29,30,31],"Atherosclerotic Renal Artery Stenosis","Fractional Flow Reserve","Optimal Medical Therapy","Stent Implantation",[28,29,30],"NOT_YET_RECRUITING","2026-04-27",{"date":36,"type":37},"2026-04-30","ACTUAL",{"date":39,"type":22},"2026-03-31",{"date":41,"type":22},"2028-03-31",{"name":43,"class":44},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",20,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100601867","qfr-for-branch-stenosis-after-single-stent-in-bifurcation-lesions-100601867","NCT07116083","µQFR for Branch Stenosis After Single Stent in Bifurcation Lesions","Diagnostic Performance of µQFR for Residual Functional Stenosis in Bifurcation Lesions After Single-stenting Strategy","Inclusion Criteria:\n\n1. Age ≥ 18 years and provision of written informed consent for biospecimen donation upon hospital admission.\n2. Clinical suspicion or diagnosis of CAD requiring coronary angiography and physiological assessment.\n3. Angiographically confirmed true bifurcation lesions, including but not limited to: left main-left anterior descending-left circumflex (LM-LAD-LCx), left anterior descending-diagonal (LAD-Dg), left circumflex-obtuse marginal (LCx-OM), and right coronary artery-posterior left ventricular-posterior descending artery (RCA-PLV-PDA).\n4. Bifurcation lesion vessel diameter ≥ 2.5 mm with visually estimated angiographic diameter stenosis ≥ 50%.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction.\n2. Cardiogenic shock or severe heart failure (Killip class IV).\n3. Serum creatinine \\> 150 μmol\u002FL or estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m² calculated using the CKD-EPI formula.\n4. Known allergy to iodinated contrast media.\n5. History of coronary artery bypass graft surgery.","18 Years",{"count":55,"type":22},290,"OBSERVATIONAL","Murray-law based single-view quantitative flow ratio (µQFR) has been recommended for guiding percutaneous coronary intervention (PCI) in selective patients. However, it's reliability has not been validated in bifurcation lesions which present complex anatomy and flluid conditions before and after PCI. The goal of this study is to investigate the diagnostic performance of µQFR in side branch after single-stent treatment for bifurcation lesions in patient with obstructive coronary artery diseases.",[59,60,61,31],"Coronary Artery Disease","Coronary Artery Disease (Left Main)","Obstructive Coronary Artery Disease",[63,64],"Functional Flow Reserve","Quantitative Flow Ratio","RECRUITING","2026-01-28",{"date":68,"type":37},"2026-02-02",{"date":70,"type":37},"2025-08-13",{"date":72,"type":22},"2026-10-31",{"name":74,"class":44},"Shanghai Zhongshan Hospital",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":75},"100603716","dual-anti-platelet-optimized-stent-for-high-bleeding-risk-patient-100603716","NCT07140133","Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient","DIOHR","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Male or female patient requiring a coronary angioplasty procedure according to European recommendations,\n* Patients undergoing revascularization with HT-supreme stents\n* Patient at high risk of bleeding according to ARC HBR definition (9).\n* Patient affiliated to or benefiting from a social security scheme\n* Patient who does not object to research\n\nExclusion Criteria:\n\n* Estimated lifespan \\\u003C1 year,\n* Allergy and any other contraindication to aspirin and\u002For clopidogrel listed in the summary of product characteristics,\n* Allergy to iodinated contrast media\n* Adults under legal protection (guardianship, curatorship or safeguard of justice).\n* Persons deprived of their liberty by judicial or administrative decision,\n* Patient in a period of relative exclusion from another research protocol,",{"count":84,"type":22},1200,"High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events, particularly in HBR patients, compared with longer DAPT. European guidelines therefore authorize one-month DAPT in HBR patients presenting even an acute coronary syndrome.\n\nThe HT Supreme Drug Coated Coronary Stent System (HT Supreme DES) is designed to promote reendothelialization as quickly as possible. That's why the stent is called \"HT\" Supreme, with \"HT\" standing for \"Healing Targeted\", enabling a DAPT of just 1 month in all-comers HBR patients.\n\nThanks to these features, the investigators aim to demonstrate ischemic and hemorrhagic complication rates lower than those found in the literature with other stent.",[87,88,31,89],"High Bleeding Risk Patients","Cardiology","DAPT(Dual Antiplatelet Therapy)","2025-08-21",{"date":92,"type":37},"2025-08-24",{"date":94,"type":22},"2025-09",{"date":96,"type":22},"2027-09",{"name":98,"class":44},"University Hospital, Grenoble",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100514568","cognitive-improvement-after-carotid-stenting-in-hyperbaric-oxygen-therapy-trial-100514568","NCT05980195","Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial","Cognitive Improvement After cARotid stEnting in HyperBaric Oxygen Therapy Trial (CARE-HBOT)","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. National Institute of Health stroke scale (NIHSS) ≤3\n3. Culprit vessel was the common carotid artery or extracranial internal carotid artery, involving or not involving the external carotid artery\n4. The degree of culprit arterial stenosis is 70-99 % ; based on Digital subtraction angiography (DSA) (According to North American Symptomatic Carotid Endarterectomy Trial (NASCET) method)\n5. The diameter of the target vessel between 4.0 mm - 9.0 mm\n6. Mini-mental State Examination (MMSE) score : education level-middle school ≤ 24; education level-high school ≤ 20 ; education level-college ≤ 17\n7. Baseline modified Rankin Scale (mRS) score ≤ 3\n8. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion\n2. Serious perioperative complications affecting subsequent hyperbaric oxygen therapy (such as cerebral hemorrhage, disabling stroke, etc.)\n3. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 12 months\n4. Hemorrhagic transformation after ischemic stroke within 60 days before enrollment\n5. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n6. Nervous system diseases in the past two years, characterized by transient or fixed neurological deficits (such as partial or secondary generalized seizures of epilepsy, complex or classic migraine, tumor or other intracranial space-occupying lesions, subdural hematoma, brain contusion or other post-traumatic lesions, intracranial infection, demyelinating diseases, intracranial hemorrhage, etc.), which cannot be distinguished from cerebral infarction\n7. History of stenting of an intracranial or extracranial artery\n8. Presence of any unequivocal cardiac source of embolism\n9. Chronic atrial fibrillation; paroxysmal atrial fibrillation or paroxysmal atrial fibrillation in the past 6 months, or a history of paroxysmal atrial fibrillation, requiring long-term anticoagulation\n10. Myocardial infarction in the past 30 days\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy due to known diseases (such as gastrointestinal bleeding)\n13. Contraindications to heparin, aspirin, clopidogrel, ticagrelor, anesthesia, or contrast agents\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL, international normalized ratio (INR)\\>1.5, or heparin-related thrombocytopenia or uncorrectable factors leading to bleeding\n15. Not suitable for vessel angiography or endovascular interventional therapy (such as morbid obesity; serious vascular tortuosity that hinders the safe introduction of the guiding catheter)\n16. Severe hepatic and renal dysfunction\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cognitive assessment and follow-up could not be completed due to factors such as severe aphasia, neuropsychological illness or mental illness or dysarthria and inability to communicate\n22. History of drug or alcohol abuse, head trauma or central nervous system infection; current use of drugs that affect cognition\n23. Combined with diseases that are not suitable for hyperbaric oxygen therapy (such as untreated pneumothorax, uncontrolled epilepsy, claustrophobia, angle-closure glaucoma, cavitary pulmonary tuberculosis, etc.)\n24. Enrollment in another study that would conflict with the current study","75 Years",{"count":108,"type":22},90,[25],"The purpose of CARE-HBOT study is to evaluate whether patients with symptomatic severe carotid artery stenosis with cognitive impairment who underwent hyperbaric oxygen therapy plus standard medical treatment after stent implantation could improve their cognitive function compared with those who underwent standard postoperative medical treatment.",[112,113,114,31],"Carotid Stenosis","Cognitive Impairment","Hyperbaric Oxygen Therapy","2024-07-17",{"date":117,"type":37},"2024-07-18",{"date":119,"type":22},"2024-07-16",{"date":121,"type":22},"2025-12-31",{"name":123,"class":44},"Beijing Tiantan Hospital"]